3Tapiovaara H,Alitalo R,Vaheri A.Plasminogen activation on tumor cell surface and its involvement in huma leukemia[J].Adv Cancer Res,1996,69:101.
4Bell WR.The fibrinolytic system in neoplasia[J].Semin Thromb Hemost,1996,22(6):459.
5Kutz SM.Nickey SA,White LA,et al.Induced PAI-1 mRNA expression and targeted protein accumulation are early G1 events in Serum-stimulated rat kidney cells[J].Cell Physiol,1997,170(1):8.
6Henry M,Tregouet DA,Alessi MC,et al.Metabolic determinants are much more important than genetic polymorphisms in determining the PAI-1 activity and antigen plasma concentrations:a family study with part of the Stanislas Cohort[J].Arterioscler Thromb Vasc Biol,1998,18(1):84.
7Henry M,Chomiki N,Scarabin PY,et al.Five frequent polymophisms of the PAI-1 gane:lack of association between genotypes,PAI activity,and triglyceride levels in healthy population[J].Arterioscler Thromb Vase Biol,1997,17(5):851.
8Kimura H,Gejyo F,Suzuki Y,et al.Polymorphisms of angiotensin converting enzyme and plasminogen activator inhibitor-1 genes in diabetes and macroangiopathy[J].Kidney Int,1998,54(5):1659.
9Grancha S,Estelles A,Tormo G,et al.Plasminogen activator inhibitor-1 (PAI-1) promoter 4G/5G genotype and increased PAI-1 circulating levels in postmenopausal women with coronary artery disease[J].Thromb Haemost,1999,81(4):516.
10Wong TY,Ponn P,Szeto CC,et al.Association of plasminogen activator inhibitor-1 4G/4G genotype and type 2 diabetic nephropathy in Chinese patients[J].Kidney Int,2000,57(2):632.
2American Diabetes Association. Standards of medical care for patients with diabetes mellitus (position statement) [ J ]. Diabetes Care, 2003, 26(Suppl 1) : S33 - S50.
3Asian-Pactific Type 2 Diabetes Policy Group. Type 2 diabetes practical targets and treatments (Third edition)[C]. 2002.
4American Diabetes Association. Treatment of hypertension in adults with diabetes (position statement) [J]. Diabetes Care,2003, 26(Suppl 1): S83- S86.
5邓义斌，中华医学杂志，1997年，77卷，672页
6Meryer J, Szukies B,Neubauer k, etal. Extracellular matrix proteins as a early markers in diabetic nephropathy 〔J〕. EurJ Clin Chem Clin Biochem, 1995,33:211～215.
7Kreisbery JI, Radmile RA, Ayosh J, et al. High glucose elevates c-fos and c-juntranscripts and proteins in mesangial cell cultures 〔J〕. kidney Int, 1994,45:105～112.
8Eiji Ⅰ, Yoshilci N, shigeichj S. Serum type Ⅲ、Ⅳ collagens and TIMP inpatient with type 2 diabetes mellitus 〔J〕. life Sci, 1996,58:1331～1337.
9Banu U, Hara H, Okarnura M, et al. Urinary excretion of type Ⅳ collagen andlaminin in the evaluation of nephropathy in NIDDM: comparision with urinary albumin andmarkers of tubular dysfunction and/or damage 〔J〕. Diabetes Res Clin Pract, 1995,29:57～67.
10Meyer Ⅱ, Szukics B, Neubauer k, et al. Extracellullar matrix proteins as earlymarkers in diabetic nephropathy 〔J〕. Eur J Clin Chem Clin Biochem, 1995,33:211～219.
